Diminished neutralization responses towards SARS-CoV-2 Omicron VoC after mRNA or vector-based COVID-19 vaccinations

3 Henning Jacobsen^{#,1}, Monika Strengert^{#,2,3}, Henrike Maaβ^{*,1}, Mario Alberto Ynga Durand^{*,1}, Barbora

4 Kessel², Manuela Harries², Ulfert Rand¹, Leila Abassi¹, Yeonsu Kim¹, Tatjana Lüddecke¹, Pilar Hernandez²,

5 Julia Ortmann², Jana-Kristin Heise², Stefanie Castell², Daniela Gornyk², Stephan Glöckner², Vanessa

6 Melhorn², Yvonne Kemmling², Berit Lange^{2,5}, Alex Dulovic⁴, Julia Häring⁴, Daniel Junker⁴, Nicole

- 7 Schneiderhan-Marra⁴, Markus Hoffmann^{6,7}, Stefan Pöhlmann^{6,7}, Gérard Krause^{2,3,5,§}, Luka Cicin-Sain^{1,5,8,§}
- 8 1 Helmholtz Centre for Infection Research, Department of Viral Immunology, Braunschweig, Germany
- 9 2 Helmholtz Centre for Infection Research, Department of Epidemiology Braunschweig, Germany
- 10 3 TWINCORE, Centre for Experimental and Clinical Infection Research, a joint venture of the Hannover
- 11 Medical School and the Helmholtz Centre for Infection Research, Hannover, Germany
- 12 4 NMI Natural and Medical Sciences Institute at the University of Tübingen, Reutlingen, Germany
- 13 5 German Centre for Infection Research (DZIF), partner site Hannover-Braunschweig, Germany
- 14 6 Deutsches Primatenzentrum, Leibniz-Institut für Primatenforschung, Göttingen, Germany
- 15 7 Faculty of Biology and Psychology, Georg-August-University Göttingen, Germany
- 16 8 Centre for Individualized Infection Medicine (CIIM), a joint venture of Helmholtz Centre for Infection
- 17 Research and Medical School Hannover, Germany
- 18

19 # (first authors), * (second authors), \$ (corresponding authors): these authors contributed equally.

- 20
- 21 Corresponding authors contact details:
- 22 Luka Cicin-Sain, Phone number: +49 (0)53161814616, Email address: luka.cicin-sain@helmholtz-hzi.de,
- 23 Postal address: Inhoffenstraße 7, 38124 Braunschweig, Germany.
- 24
- 25

26 Abstract

27 SARS-CoV-2 variants accumulating immune escape mutations provide a significant risk to vaccine-28 induced protection. The novel variant of concern (VoC) Omicron (B.1.1.529) has the largest number of 29 amino acid alterations in its Spike protein to date. Thus, it may efficiently escape recognition by neutralizing 30 antibodies, allowing breakthrough infections in convalescent and vaccinated individuals. We analyzed 31 neutralization activity of sera from individuals after vaccination with all mRNA-, vector- or heterologous 32 immunization schemes currently available in Europe by *in vitro* neutralization assay at peak response 33 towards SARS-CoV-2 B.1, Omicron, Beta and Delta pseudotypes and also provide longitudinal follow-up data from BNT162b2 vaccinees. All vaccines apart from Ad26.CoV2.S showed high levels of responder 34 35 rates (93-100%) towards SARS-CoV-2 wild-type, but some reductions in neutralizing Beta and Delta VoC 36 pseudotypes. The novel Omicron variant had the biggest impact, both in terms of response rates and 37 neutralization titers. Only mRNA-1273 showed a 100% response rate to Omicron and induced the highest 38 level of neutralizing antibody titers, followed by heterologous prime-boost approaches. Homologous 39 BNT162b2 vaccination or vector-based AZD1222 or Ad26.CoV2.S performed less well with peak 40 responder rates of 33%, 50% and 9%, respectively. However, Omicron responder rates in BNT162b2 41 recipients were maintained in our six month longitudinal follow-up indicating that individuals with cross-42 protection against Omicron maintain it over time. Overall, our data strongly argues for urgent booster doses 43 in individuals who were previously vaccinated with BNT162b2, or a vector-based immunization scheme.

44 Keywords

45 SARS-CoV-2, Omicron B.1.1.529, variants of concern, protective immunity, neutralization, COVID-19 46 vaccination

- 47
- 48

49 1. Introduction

50 Since its emergence in late 2019, SARS-CoV-2 has caused a pandemic with more than 270 million 51 confirmed infections and more than 5 million deaths (1). While a series of vaccines have been developed 52 with unprecedented speed and were successfully deployed to limit the burden of COVID-19, it became 53 quickly apparent that novel SARS-CoV-2 variants had evolved, mainly in areas of high virus prevalence. 54 Those emerging variants have accumulated mutations in the surface-exposed Spike protein, which increase 55 virus transmissibility or promote evasion from the host immune response (2-4). Immune escape was most 56 pronounced in SARS-CoV-2 variants Beta (B.1.351) and the currently globally dominating Delta 57 (B.1.617.2), at least until recently. However, the November 2021 emergence of the variant B.1.1.529 58 (Omicron) in South Africa has raised strong concerns as its unusually high number of amino acid alterations 59 in the Spike protein will likely contribute to an increased reinfection risk or breakthrough infections 60 following vaccination (5). By now, a series of studies using samples from convalescent and vaccinated 61 individuals have addressed the impact of Omicron on vaccination or infection-induced antibody 62 neutralization, using either live-, pseudovirus neutralization or *in vitro* binding assays (6-14). These studies 63 have shown clear losses of neutralization capacity against the Omicron variant but did not comprehensively address antibody responses in various vaccination regimens or over time. In contrast, we provide here a 64 65 comprehensive assessment of vaccination schemes approved in the European Union and the UK, using an 66 Omicron, Beta, Delta or wild-type (B.1) pseudo-neutralization assay at peak response after approximately

67 four weeks and in a longitudinal six month follow-up for BNT162b2.

68 2. Methods

69 2.1 Sample collection and ethics statement

70 Serum samples analysed in this study originate from vaccinated participants of the multi-local and serial 71 cross-sectional prevalence study on antibodies against SARS-CoV-2 in Germany (MuSPAD) study, a 72 population-based SARS-CoV-2 seroprevalence study in eight regions of Germany from July 2020 to 73 August 2021. The study was approved by the Ethics Committee of the Hannover Medical School 74 (9086 BO S 2020) and was in line with the Declaration of Helsinki. Briefly, MuSPAD is a successive 75 cross-sectional study where certain locations were sampled longitudinally within a 3-4 month interval (15). 76 Recruitment of eligible participants (>18 years) was based on age- and sex-stratified random sampling with 77 information provided by the respective local residents' registration offices. Basic sociodemographic data 78 and information on pre-existing medical conditions including a previous SARS-CoV-2 infection or 79 vaccination are self-reported and were documented with the Research system PIA (Prospective Monitoring 80 and Management-App) at the study center. Peripheral blood was obtained by venipuncture using a serum 81 gel S-Monovette (Sarstedt) and further processed according to the manufacturer's instructions. Serum was 82 then aliquoted at the German Red Cross Institute of Transfusion Medicine and Immunohematology and 83 transported on dry ice to the Hannover Unified Biobank for long-term storage.

84 For this study, we selected samples from 82 vaccinees from the available MuSPAD sample pool to contain 85 mRNA, vector and heterologous immunization schemes. Selection was primarily based on a consistent 21-86 35 day ΔT range from a complete vaccination until sampling with comparable age and gender distribution between vaccination schemes, if available paired longitudinal follow-up samples were selected of samples 87 88 taken at peak response. None of the donors reported a positive SARS-CoV-2 antigen or PCR test result 89 when questioned at the study center at the time of the blood draw. Additionally, all collected serum samples 90 were non-reactive for nucleocapsid-specific IgG as determined with a previously published multiplex 91 immunoassay MULTICOV-AB that contains SARS-CoV-2 Spike and nucleocapsid antigens (Supplementary Table S3, (16)), therefore excluding confounders due to infections superposed on 92 93 vaccination in our cohort. Vaccination details with basic sociodemographic information and pre-existing 94 conditions such as hypertension, cardiovascular disease, diabetes, lung disease, immunosuppression or 95 cancer of participants are provided in Table 1 and Supplementary Table S1. As controls, the first WHO 96 International Standard for human anti-SARS-CoV-2 immunoglobulin (code: 20/136) from the National

- 97 Institute for Biological Standards and Control (NIBSC) or pre-pandemic sera samples from an anonymized
- 98 Hepatitis A and Influenza virus vaccination response study at the Helmholtz Centre for Infection Research
- 99 in 2014 (Hannover Medical School Ethics Committee approval number 2198-2021) were used.

100 2.2 Cell culture

101 Vero E6 (ATCC CRL-1586), and 293T (DSMZ ACC-635) were maintained in DMEM medium 102 supplemented with 10% fetal bovine serum (FBS), 2 mM L-glutamine, 100 U/ml penicillin and 100 μ g/ml 103 streptomycin at 37 °C in a 5% CO₂ atmosphere. All cell lines used within this study were below a passage 104 of 50 and were regularly checked for mycoplasma contamination. Transfection of 293T cells was performed 105 using calcium phoenhete

- 105 using calcium-phosphate.
- 106 *2.3 Plasmids*

Plasmids encoding SARS-CoV-2 Spike B.1 (human codon optimized, 18 amino acid truncation at C terminus) and SARS-CoV-2 spike of Beta (B.1.351) and Delta (B.1.617.2) have been previously reported
 (17,10) The second s

- 109 (17-19). The expression vector for SARS-CoV-2 Spike of Omicron (based on isolate hCoV 110 19/Botswana/R40B58_BHP_3321001245/2021; GISAID Accession ID: EPI_ISL_6640919) was
- 111 generated by Gibson assembly (13). All plasmids were sequence-confirmed by Sanger sequencing prior to
- generated by Gloson assembly (13). All plasmids were sequence-confirmed by Sanger sequencing prior to
- use. Supplementary Table S2 provides an overview of Spike protein amino acid mutations used for SARS-
- 113 CoV-2 pseudotype construction compared to the parental strain B.1.

114 2.4 Pseudotyping

115 Generation of rhabdoviral pseudotypes harboring SARS-CoV-2 Spike proteins was performed as described

116 (20). In brief, 293T cells were transfected with pCG1 plasmids expressing different SARS-CoV-2 Spike

117 proteins, using calcium-phosphate. 24 h post transfection, cells were infected with a replication-deficient

118 reporter VSV-G (VSV* Δ G-Fluc) at an MOI of 3 for 1 h at 37 °C (21). Cells were washed once with PBS

and medium containing anti-VSV-G antibody (culture supernatant from L1-hybridoma cells) was added to

120 neutralize residual input virus. The cell culture supernatant was harvested after 16 hours, and cellular debris

121 was removed by centrifugation at 2000 g for 5 min at 4 °C. Aliquots were stored at -80°C until use.

- 122 2.5 Neutralization assay
- 123 For pseudovirus neutralization, serum samples and controls were heat-inactivated at 56 °C for 30 min. Thawed samples and controls were stored at 4°C for no longer than 48 hours, prior to use. In a 96-well 124 125 microtiter plate, serum samples were 2-fold serially diluted in cell culture medium (DMEM, 5 % FBS, 1% 126 P/S, 1% L-Glu) with a dilution range of 1:10 to 1:5120. Pre-diluted samples were incubated with an equal 127 volume of Spike protein-bearing viral particles (approximately 200 - 500 ffu/well) at 37 °C for 1 h. After 128 incubation, the sample-virus mixture was transferred to VeroE6 cells at 100% confluence which were 129 seeded the day before. Cells were incubated at 37 °C for 24 ± 2 h, while infected cells were visualized using 130 an IncuCyte S3 (Sartorius) performing whole-well scans (4x) in phase contrast and green fluorescence 131 settings. Automated segmentation and counting of fluorescent foci defined as GFP⁺-single cells was performed using the IncuCyte GUI software (versions 2019B Rev1 and 2021B). Raw data were plotted in 132 GraphPad prism version 9.0.2 and FRNT₅₀ was calculated with a variable slope, four-parameter regression 133 134 analysis. Non-responders were defined as subjects with undetectable neutralization titers at an initial serum dilution of 1:10. FRNT₅₀ values of those individuals were arbitrarily set to 1. All experiments were 135 136 performed with internal standard controls (pool of all tested sera), negative controls and virus-only controls 137 to assess the nominal virus input for every single measurement.
- 138 2.6 Data analysis and statistics
- 139 Initial results collation and matching to metadata was done in Excel 2016 and R 4.1.0. Graphs and statistical
- calculations were performed using GraphPad Prism version 9.0.2 for Windows (GraphPad Software). For
- 141 analysis of neutralization assay results, a Shapiro-Wilk test was used to determine normality. Focus

142 Reduction Neutralization titer with a 50% neutralization cut-off (FRNT₅₀) was calculated using a four-

parameter regression analysis function. $FRNT_{50}$ values from non-responders were set to 1 for graphical

144 presentation only. A non-parametric Friedman's test followed by Dunn's multiple comparison analysis was

used to compare neutralization results to different viruses in a pair-wise manner for matched samples. Two-

- tailed Wilcoxon matched-pairs signed rank test was used to compare neutralization of longitudinal results.
- 147 A p-value of less than 0.05 was considered statistically significant.
- 148 2.7 *Role of the funders*

This work was financially supported by the Initiative and Networking Fund of the Helmholtz Association 149 150 of German Research Centres through projects "Virological and immunological determinants of COVID-19 151 pathogenesis - lessons to get prepared for future pandemics (KA1-Co-02 "COVIPA") to LCS and grant number SO-96 to GK, by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) 152 under Germany's Excellence Strategy - EXC 2155 "RESIST" - Project ID 39087428 to LCS, and 153 154 intramural funds of the Helmholtz Centre for Infection Research. SP was supported by BMBF (01KI2006D, 155 01KI20328A, 01KX2021), the Ministry for Science and Culture of Lower Saxony (14-76103-184, MWK 156 HZI COVID-19) and the German Research Foundation (DFG; PO 716/11-1, PO 716/14-1). The funders 157 had no role in study design, data collection, data analysis, interpretation, writing or submission of the 158 manuscript. All authors had complete access to the data and hold responsibility for the decision to submit 159 for publication.

160 **3. Results**

Neutralization responses towards B.1, B.1.1.529, B.1.351, and B.1.617.2 Spike-expressing rhabdoviral 161 162 pseudotypes were analyzed in serum samples from 82 individuals vaccinated with either a single dose of 163 Ad26.COV2.S, homologous two-dose BNT162b2, mRNA-1273 or AZD1222 vaccination, or heterologous 164 AZD1222-BNT162b2 or AZD1222-mRNA-1273 vaccination at peak response, approximately four weeks 165 after the last dose. While the WHO international standard serum showed detectable neutralization against all variants including Omicron, showing excellent sensitivity of our assay, compared to previous studies 166 167 (22), pre-pandemic control sera from 2014 (n=4) showed no measurable neutralization levels 168 (Supplementary Table S3). Neutralization potency towards Beta VoC pseudotypes were clearly reduced for all vaccination schemes, however Omicron had the strongest effect across all samples tested (Fig. 1). 169 170 Vaccination with vector-based Ad26.CoV2.S performed least well (Fig. 1a), with only 73% responders against the B.1 variant, 18% for the Beta and 9% for Omicron VoC. Homologous vaccination with either 171 AZD1222 or BNT162b2 performed better against Omicron, with 50% or 33% responders, respectively 172 173 (Fig. 1b, 1c). Heterologous immunization with these two vaccines (AZD1222-BNT162b2) showed a 174 response rate of 80% (Fig. 1d). Heterologous vaccination with AZD1222-mRNA-1273 had a similar 175 response rate of 82% (Fig. 1e), but homologous immunization with mRNA-1273 had the highest Omicron response rate of 100% (Fig. 1f). Non-parametrical statistical comparisons showed a highly significant 176 177 reduction in serum titers when Omicron neutralization was compared to B.1 for all vaccination schemes 178 (Fig 1a-e). There was no tendency of age, sex, or pre-existing medical conditions to modify the responder 179 status against Omicron in our cohort (Supplementary Table S3). To assess the impact of immune escape 180 with more detail, we focused on the responders and compared geometric means of their $FRNT_{50}$ titers 181 (GMT). Importantly, fold-changes for groups that included non-responders are not provided in Fig. 1, 182 because this would lead to highly artificial results and possibly over-interpretation. We therefore present 183 the percentage of responders as primary outcome and provide GMT fold changes where calculation is reasonable (100% responders in both arms). Furthermore, for each vaccination regimen, we defined the 184 185 responder subgroups (excluding non-responders defined as subjects with undetectable neutralization titers 186 at an initial 1:10 serum dilution in either group) and compared the fold-reduction for titers that could be 187 quantified (see Table 2). In these subsets, we observed an approximate 15-fold reduction in GMT for most 188 vaccinations, except BNT162b2, where the reduction was 28-fold at peak response. This was consistent

with the high frequency of non-responders in this subset, additionally arguing for weaker protection againstthe Omicron variant in this cohort.

191 Since BNT162b2 is very commonly used, we tested the neutralization potency in BNT162b2 recipients at approximately six months post immunization as well. Similar to the peak responses, we observed a 192 193 significantly weaker neutralization of the Omicron compared to the B.1 pseudotype and only 47% 194 responders against the newly emerging VoC (Fig. 2a). Beta neutralization was slightly reduced, whereas 195 Delta neutralization was at the same levels as B.1 at the late time point (Fig. 2a). To understand the 196 longitudinal dynamic of humoral immunity, we used paired sera from BNT162b2 vaccine recipients at four 197 weeks (already shown in Fig. 1c) and at six months post second dose which allowed us to compare intra-198 individual titer changes over time (Fig. 2b-d). While the neutralization of B.1 (Fig. 2b) and of the Delta 199 VoC (Fig. 2d) decreased significantly over time, the time dependent reduction was less pronounced for the 200 Beta (Fig. 2c) or the Omicron VoC (Fig. 2e). Moreover, all Omicron responders identified early after 201 vaccination had still detectable neutralizing capacity at the late time points and two additional responders 202 were identified in the late phase only (Fig. 2e). Therefore, the differences in neutralization titers between 203 B.1 and Omicron responders were less pronounced at the late time points than at peak response (Table 2).

In sum, homologous mRNA-1273 vaccination resulted in the highest responder rate, Ad26.CoV2.S in the
 lowest within the vaccination peak response phase, and a longitudinal follow-up showed that Omicron
 responses, while reduced, can be rather durable if present in the first place.

207 Discussion

We provide a comprehensive overview of neutralization responses from all currently available COVID-19 208 209 vaccination schemes in the European Union and the UK not only towards the Omicron VoC, but also 210 towards Beta and Delta VoC compared to the parental strain B.1. We expand on previous findings (11, 12) that neutralization towards Omicron is particular poor after vaccination with vector-based formulations 211 even within the peak phase shortly after vaccination. Also consistent with other reports (13, 14), we 212 213 observed a still surprisingly low cross-neutralization in BNT162b2 recipients. While some time differences 214 exist between doses for homologous and heterologous vaccines, sampling periods after the complete 215 scheme were within peak response making an earlier waning of BNT162b2-induced antibodies highly 216 unlikely. While age impacts antibody titers and neutralization potency (23-25), our group of BNT162b2 recipients is slightly younger compared to the other vaccinees making age an unlikely contributor to our 217 218 observation. Additionally, no tendency became apparent for gender and comorbidities either. Considering 219 our relatively small sample size, it is however possible that this low overall response in the BNT162b2 group was a spurious observation. Nevertheless, samples showing any cross-neutralizing responses early 220 221 on remained responsive to Omicron six months later. Notably, all mRNA-1273 recipients and 80% of those receiving any heterologous vaccination showed a detectable neutralization against Omicron in our analysis. 222 223 It is not clear, why these vaccination protocols were more efficient against the Omicron pseudotype than 224 BNT162b2, but it is indicative that the baseline neutralization against the B.1 pseudotype was stronger in 225 all of them in our sample cohorts.

226 The detectable responsiveness to the Omicron pseudotype in all mRNA-1273 recipients differed from 227 previous reports where usually several samples showed no measurable neutralization against Omicron (12, 228 14, 26). This might be due to sampling differences, a result of increased sensitivity in our assay, or both. 229 We chose responder rates as primary outcome because this is a less biased expression than fold changes if titers from non-responsive individuals are calculated. For the same reason, we used a non-parametric assay 230 231 to evaluate differences, allowing us to include samples that were below detection threshold, but obviously 232 very low in titer. Fold changes were calculated separately on a subset of samples that showed detectable 233 titers in all circumstances. We observed an approximately 15-fold reduction in most vaccination regimens 234 except BNT162b2, adding evidence that Omicron cross-neutralization was impaired in this cohort. Our 235 studies has several limitations. First, sample numbers in our cohort are low. They are however comparable 236 to the majority of other studies to date and are well-matched on age and sex. Second, while our mean 55

237 day sampling time period after Ad26.CoV2.S administration is slightly longer than the four week sampling 238 interval of the other vaccination schemes, our results are in line with others who reported poor Omicron 239 neutralization following vaccination with Ad26.CoV2.S both at one and five months after dosing (11, 12). 240 Third, while self-reported information about a previous SARS-CoV-2 infection or vaccination can impact 241 study outcome, two recent publications found a 98% consistency for vaccination type and 95% for vaccination date between self-reported and administrative records or a positive predictive value of 98.2% 242 243 and a negative predictive value of 97.3% between a self-reported vaccination and the detection of SARS 244 CoV-2 antibodies (27, 28). Last, we only examine vaccination-induced antibody titers, omitting from our 245 study people with previous infections or boosters. While these information would be valuable, we could 246 not provide this dataset in a reasonably short time. Hence, it remains to be determined if boosters or 247 convalescence has impacts that specifically improve neutralization efficacy by defined vaccination 248 protocols.

Following current recommendations, a booster vaccination is generally advised after six months in many countries. Although our results do not necessarily predict failure of vaccine effectiveness and omit measuring cellular immunity or non-neutralizing antibody effects, it does however suggest that active protection against the Omicron VoC may be reduced in many vaccinated individuals. Hence, booster vaccination might be advised at earlier stages, especially for at-risk groups in the absence of a precise and clinically relevant correlate of protection.

255 Overall, we provide further evidence that that amino acid mutations accumulated in the B.1.1.529 Spike

256 protein serve to escape vaccine-induced protection. In the absence of conclusive data on infectivity and

257 disease severity, development of adapted second generation vaccinations, booster doses and careful

258 monitoring of future variants of concern appears warranted.

259 Contributors

MS, HJ, LCS conceived the study. MS, GK, BL, SC, NSM, SP and LCS procured funding. GK, BL, MS,
MaH and DG designed the population-based cohort this study is based on. HJ, MS and LCS designed the
experiments. HJ, HM, MYD, UR, LA, YK and TL performed the experiments. MHa, BK, MS, JH, MYD

and HM performed data analysis. MS, HJ, HM, MYD generated figures and tables. MS, BK, HJ, LCS

verified the underlying data. MHo, SP provided reagents. AD, DJ, JH, MS, BK, PH, BL, SC, MHa, DG,

265 SG, JKH, VM, YvK were involved in sample or data collection and project administration. MS, HJ, LCS

wrote the manuscript. All authors critically reviewed and approved the final manuscript.

267 **Declaration of Interest**

268 NSM was a speaker at Luminex user meetings in the past. The Natural and Medical Sciences Institute at

the University of Tübingen is involved in applied research projects as a fee for services with the LuminexCorporation. The other authors declare no competing interest.

270 Corporation. The other authors declare no competing int

271 Acknowledgments

We want to thank again all parties involved in any capacity in making MuSPAD happen. Most of all the study participants for their willingness and commitment to make this study possible and all colleagues at the HZI, the Hannover Unified Biobank and the DRK Institute of Transfusion Medicine and Immunohematology who contributed to project administration, organization and sample processing. We thank Daniela Lenz, Ayse Barut, Inge Hollatz-Rangosch and Fawad Khan for excellent technical assistance during this study.

278 Data Sharing Statement

Raw data is provided with the manuscript. Additional data is available upon request from the correspondingauthors.

281 References

- 282 1. WHO. WHO Coronavirus (COVID-19) Dashboard 2021 [Available from: https://covid19.who.int/. 283 2. Altmann DM, Boyton RJ, Beale R. Immunity to SARS-CoV-2 variants of concern. Science. 284 2021;371(6534):1103-4. Lopez Bernal J, Andrews N, Gower C, Gallagher E, Simmons R, Thelwall S, et al. Effectiveness of 285 3. 286 Covid-19 Vaccines against the B.1.617.2 (Delta) Variant. N Engl J Med. 2021;385(7):585-94. 287 Tao K, Tzou PL, Nouhin J, Gupta RK, de Oliveira T, Kosakovsky Pond SL, et al. The biological and 4. 288 clinical significance of emerging SARS-CoV-2 variants. Nat Rev Genet. 2021;22(12):757-73. 289 5. WHO. Classification of Omicron (B.1.1.529): SARS-CoV-2 Variant of Concern 2021 [Available 290 from: https://www.who.int/news/item/26-11-2021-classification-of-omicron-(b.1.1.529)-sars-cov-2-291 variant-of-concern. 292 Zhang L, Li Q, Liang Z, Li T, Liu S, Cui Q, et al. The significant immune escape of pseudotyped 6. 293 SARS-CoV-2 Variant Omicron. Emerg Microbes Infect. 2021:1-11. 294 Cele S, Jackson L, Khan K, Khoury DS, Moyo-Gwete T, Tegally H, et al. SARS-CoV-2 Omicron has 7. 295 extensive but incomplete escape of Pfizer BNT162b2 elicited neutralization and requires ACE2 for 296 infection. medRxiv. 2021. 297 8. Dejnirattisai W, Shaw RH, Supasa P, Liu C, Stuart AS, Pollard AJ, et al. Reduced neutralisation of 298 SARS-COV-2 Omicron-B. 1.1. 529 variant by post-immunisation serum. medRxiv. 2021. 299 9. Wilhelm A, Widera M, Grikscheit K, Toptan T, Schenk B, Pallas C, et al. Reduced Neutralization of 300 SARS-CoV-2 Omicron Variant by Vaccine Sera and Monoclonal Antibodies. medRxiv. 2021. 301 Schubert M, Bertoglio F, Steinke S, Heine PA, Ynga-Durand MA, Zuo F, et al. Human serum from 10. 302 SARS-CoV-2 vaccinated and COVID-19 patients shows reduced binding to the RBD of SARS-CoV-2 303 Omicron variant. medRxiv. 2021. 304 Schmidt F, Muecksch F, Weisblum Y, Silva JD, Bednarski E, Cho A, et al. Plasma neutralization 11. 305 properties of the SARS-CoV-2 Omicron variant. medRxiv. 2021. 306 12. Rössler A, Riepler L, Bante D, Laer Dv, Kimpel J. SARS-CoV-2 B.1.1.529 variant (Omicron) evades 307 neutralization by sera from vaccinated and convalescent individuals. medRxiv. 2021. 308 13. Hoffmann M, Krüger N, Schulz S, Cossmann A, Rocha C, Kempf A, et al. The Omicron variant is 309 highly resistant against antibody-mediated neutralization - implications for control of the COVID-19 310 pandemic. bioRxiv. 2021. Garcia-Beltran WF, St. Denis KJ, Hoelzemer A, Lam EC, Nitido AD, Sheehan ML, et al. mRNA-311 14. 312 based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant. 313 medRxiv. 2021. 314 Gornyk D, Harries M, Glöckner S, Strengert M, Kerrinnes T, Heise J-K, et al. SARS-CoV-2 15. 315 seroprevalence in Germany. Deutsches Ärzteblatt international. 2021. 316 Becker M, Strengert M, Junker D, Kaiser PD, Kerrinnes T, Traenkle B, et al. Exploring beyond 16. 317 clinical routine SARS-CoV-2 serology using MultiCoV-Ab to evaluate endemic coronavirus cross-318 reactivity. Nature communications. 2021;12(1):1152. 319 Hoffmann M, Zhang L, Kruger N, Graichen L, Kleine-Weber H, Hofmann-Winkler H, et al. SARS-17. 320 CoV-2 mutations acquired in mink reduce antibody-mediated neutralization. Cell Rep. 321 2021;35(3):109017. 322 18. Hoffmann M, Arora P, Gross R, Seidel A, Hornich BF, Hahn AS, et al. SARS-CoV-2 variants B.1.351 323 and P.1 escape from neutralizing antibodies. Cell. 2021;184(9):2384-93 e12. 324 Brinkmann C, Hoffmann M, Lubke A, Nehlmeier I, Kramer-Kuhl A, Winkler M, et al. The 19. 325 glycoprotein of vesicular stomatitis virus promotes release of virus-like particles from tetherin-positive
- 326 cells. PLoS One. 2017;12(12):e0189073.

327 20. Kleine-Weber H, Elzayat MT, Wang L, Graham BS, Muller MA, Drosten C, et al. Mutations in the
328 Spike Protein of Middle East Respiratory Syndrome Coronavirus Transmitted in Korea Increase
329 Resistance to Antibody-Mediated Neutralization. J Virol. 2019;93(2).

330 21. Berger Rentsch M, Zimmer G. A vesicular stomatitis virus replicon-based bioassay for the rapid 331 and sensitive determination of multi-species type I interferon. PLoS One. 2011;6(10):e25858.

332 22. Aggarwal A, Stella AO, Walker G, Akerman A, Milogiannakis V, Brilot F, et al. SARS-CoV-2

333 Omicron: evasion of potent humoral responses and resistance to clinical immunotherapeutics relative to 334 viral variants of concern. medRxiv. 2021:2021.12.14.21267772.

Naaber P, Tserel L, Kangro K, Sepp E, Jürjenson V, Adamson A, et al. Dynamics of antibody
response to BNT162b2 vaccine after six months: a longitudinal prospective study. The Lancet Regional
Health - Europe. 2021;10:100208.

Steensels D, Pierlet N, Penders J, Mesotten D, Heylen L. Comparison of SARS-CoV-2 Antibody
Response Following Vaccination With BNT162b2 and mRNA-1273. Jama. 2021;326(15):1533-5.

Shrotri M, Fragaszy E, Geismar C, Nguyen V, Beale S, Braithwaite I, et al. Spike-antibody
 responses to ChAdOx1 and BNT162b2 vaccines by demographic and clinical factors (Virus Watch study).

342 medRxiv. 2021:2021.05.12.21257102.

26. Doria-Rose NA, Shen X, Schmidt SD, O'Dell S, McDanal C, Feng W, et al. Booster of mRNA-1273

344 Vaccine Reduces SARS-CoV-2 Omicron Escape from Neutralizing Antibodies. medRxiv.

345 2021:2021.12.15.21267805.

27. Pritchard E, Matthews PC, Stoesser N, Eyre DW, Gethings O, Vihta K-D, et al. Impact of

vaccination on new SARS-CoV-2 infections in the United Kingdom. Nature Medicine. 2021;27(8):1370-8.

34828.Siegler AJ, Luisi N, Hall EW, Bradley H, Sanchez T, Lopman BA, et al. Trajectory of COVID-19

Vaccine Hesitancy Over Time and Association of Initial Vaccine Hesitancy With Subsequent Vaccination.
 JAMA Network Open. 2021;4(9):e2126882-e.

351

352

353 Table 1. Sample characteristics (na: not applicable)

354

Sample cohort (n)	ΔT (days) post- complete vaccination (mean, SD)	ΔT (days) between doses (mean, SD)	Age (years), median (IQR)	Sex (n, %)	
				Female	Male
two-dose BNT162b2 T1* (15)	28.3 (4.8)	21.2 (1.2)	50 (39-56)	12 (80.0)	3 (20.0)
two-dose BNT162b2 T2* (15)	173.6 (11.4)	21.3 (1.2)	50 (40-57)	12 (80.0)	
two-dose mRNA- 1273 (16)	28.5 (4.2)	32.0 (6.1)	56 (54-68)	11 (68.8)	5 (31.2)
first dose AZD1222, second dose mRNA-1273 (11)	28.2 (4.4)	65.4 (21.6)	68 (65-73)	7 (63.7)	4 (36.4)
first dose AZD1222, second dose BNT162b2 (15)	26.0 (4.1)	76.2 (7.7)	67 (65-69)	4 (26.7)	11 (73.4)
two-dose AZD1222 (14)	27.1 (1.2)	77.6 (1.8)	65 (63-69)	7 (50.0)	7 (50.0)
one-dose Ad26.CoV2.S (11)	55.3 (5.4)	na	61 (58-63)	7 (63.6)	4 (36.4)

* Two-dose BNT162b2 T1 and two-dose BNT162b2 T2 are paired longitudinal samples.

355 356

5 Table 2. Geometric means of responses and fold changes in Omicron responder subsets


Vaccination	GMT (95% CI) of paired <u>responders</u>					
regimen	B.1	Beta	Delta	Omicron		
two-dose mRNA-1273	526.0 (368.1-751.5)	119.6 (70.7-202.5)	481.5 (70.7-202.5)	33.2 (21.2-52.2)		
first dose AZD1222, second dose BNT162b2	902.8 (572.0-1425.0)	173.9 (109.0-277.5)	173.9 (109.0-277.5)	61.5 (44.0-85.9)		
first dose AZD1222, second dose mRNA-1273	1323.0 (740.6-2363.0)	368.9 (156.9-867.3)	923.8 (418.5-2039.0)	75.6 (41.2-138.9)		
two-dose AZD1222	186.4 (91.2-381.3)	46.4 (20.8-103.5)	95.3 (41.5-232.9)	14.6 (7.0-30.5)		
one-dose Ad26.CoV2.S*	na	na	na	na		
two-dose BNT162b2 T1 **	393.0 (213.5-723.6)	56.6 (14.3-223.5)	503.5 (275.2-921.0)	13.7 (7.8-24.1)		
two-dose BNT162b2 T2 **	82.6 (60.1-113.6)	31.3 (16.8-58.2)	85.7 (51.4-142.7)	10.9 (7.3-16.5)		
Vaccination regimen	Fold change in GMT of paired <u>responders</u>					
	B.1	Beta	Delta	Omicron		
two-dose mRNA-1273	-	-4.4	-1.1	-15.8		
first dose AZD1222, second dose BNT162b2	-	-5.2	-1.6	-14.7		
first dose AZD1222, second dose mRNA-1273	-	-3.6	-1.4	-17.5		
two-dose AZD1222	-	-4.0	-1.9	-12.8		
one-dose Ad26.CoV2.S*	-	na	na	na		
two-dose BNT162b2 T1 **	-	-6.9	-0.8	-28.7		
two-dose BNT162b2 T2 **	-	-2.6	-1.0	-7.5		

* Only one subject showed detectable neutralization titers in the Omicron assay.

** Two-dose BNT162b2 T1 and two-dose BNT162b2 T2 are paired longitudinal samples.

357


358 Figures with legends



359

Fig. 1. Impact of SARS-CoV-2 vaccination schemes on neutralization response towards Omicron (B.1.1.529) variant.

362 Vaccination-induced neutralization potency against Omicron (B.1.1.529), Beta (B. 1.351), Delta (B.1.617.2) or 363 Wuhan (B.1) pseudotypes was measured in individuals who received a vector-based vaccination with single dose 364 Ad26.CoV2.S (n=11, a), two doses of AZD1222 (n=14, b), two doses of mRNA vaccine BNT162b2 (n=15, c), a 365 heterologous two-dose vaccination with AZD1222-BNT162b2 (n=15, d) or AZD1222-mRNA-1273 (n=11, e), or two 366 doses of mRNA vaccine mRNA-1273 (n=16, f) 21 to 61 days after the last dose. FRNT₅₀ data is expressed for each 367 serum sample, bold horizontal lines and whiskers are geometric means with 95% CI. Interconnecting lines represent 368 sample data from the same donor. Non-neutralizing sample values were arbitrarily set to 1 for presentation purposes, 369 indicated by a dashed line. Fold change in neutralization potency between SARS-CoV-2 wild-type and VoC 370 pseudotypes is shown below p-values. Percentage (%) responder rates and FRNT₅₀ geometric mean titers (GMT) per 371 SARS-CoV-2 pseudotype are shown above the individual measurements. Fold change in neutralization potency and 372 GMTs for SARS-CoV-2 pseudotypes are only calculated for groups where all samples had a detectable neutralizing 373 activity, or else not applicable (na) is stated. Time between sampling and full vaccination in days is displayed as mean 374 and SD below the vaccination scheme. Statistical analysis was performed by paired non-parametric Friedman's test 375 followed by a Dunn's multiple comparison analysis. Statistical significance was defined by a value of *<0.05; ** 376 <0.01; ***<0.001; ****<0.0001.





378 Fig. 2. Longitudinal BNT162b2 neutralization response towards SARS-CoV-2 VoC Omicron (B.1.1.529).

379 Neutralization capacity towards SARS-CoV-2 Omicron (B.1.1.529), Beta (B. 1.351), Delta (B.1.617.2) or Wuhan 380 (B.1) pseudotypes was analyzed approximately six months after a two-dose BNT162b2 vaccination (n=15, a). 381 Neutralization kinetic of paired longitudinal samples towards SARS-CoV-2 B.1 (b), Beta (c), Delta (d) and Omicron 382 (e) pseudotypes is shown between T1 (n=15; mean (SD) Δ T after last dose: 28.3 (4.3)) and T2 (n=15; mean (SD) Δ T 383 after last dose: 173.6 (11.4)). Peak neutralization responses of BNT162b2-vaccinated individuals from Figure 1c are 384 displayed for clarity and comparison (b-e). FRNT₅₀ data is expressed for each serum sample, bold horizontal lines and 385 whiskers are geometric means with 95% CI. Interconnecting lines represent sample data from the same donor (a-e). 386 Non-neutralizing samples were arbitrarily set to 1 for presentation purposes, indicated by a dashed line. Fold change in neutralization potency between SARS-CoV-2 wild-type and VoC pseudotypes is shown below p-values. Percentage 387 388 (%) responder rates and FRNT₅₀ geometric mean titers (GMT) per SARS-CoV-2 pseudotype are shown above the individual measurements. Fold change in neutralization potency and GMTs for SARS-CoV-2 pseudotypes are only 389 390 calculated for groups where all samples had a detectable neutralizing activity, or else not applicable (na) is stated. 391 Statistical analysis was performed by paired non-parametric Friedman's test followed by a Dunn's multiple comparison 392 analysis (a) or a by two-tailed Wilcoxon matched-pairs signed rank test (b-e). Statistical significance was defined by